Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $174 | $2 | $2 | $13 |
| % Growth | 7,375.2% | 6.1% | -83.2% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $3 |
| Gross Profit | $174 | $2 | $2 | $10 |
| % Margin | 100% | 77.8% | 80.6% | 77.6% |
| R&D Expenses | $4 | $8 | $9 | $5 |
| G&A Expenses | $3 | $4 | $4 | $3 |
| SG&A Expenses | $6 | $7 | $7 | $5 |
| Sales & Mktg Exp. | $3 | $3 | $3 | $1 |
| Other Operating Expenses | -$0 | -$2 | -$2 | $9,073 |
| Operating Expenses | $10 | $13 | $14 | $9 |
| Operating Income | -$10 | -$11 | -$12 | $1 |
| % Margin | -5.5% | -488.6% | -537.5% | 9.8% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$2,122 |
| Pre-Tax Income | -$10 | -$12 | -$12 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$12 | -$13 | $1 |
| % Margin | -5.7% | -504.6% | -574% | 5.8% |
| EPS | -1.93 | -2.31 | -2.51 | 0.17 |
| % Growth | 16.5% | 8% | -1,576.5% | – |
| EPS Diluted | -1.93 | -2.31 | -2.51 | 0.13 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 4 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$9 | -$11 | -$12 | $2 |
| % Margin | -5.4% | -485.6% | -536.9% | 14.3% |